期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

难治和复发性急性髓细胞白血病的治疗 被引量：2

下载PDF
导出
摘要 难治和复发性急性髓细胞白血病的治疗,仍是当今临床血液学一个难以突破的问题。该文就新型化学治疗药物的应用、靶向治疗、造血干细胞移植在难治和复发性急性髓细胞白血病的治疗进展作一综述。
作者 付彬 李梅君
机构地区 辽宁医学院附属第一医院血液内科
出处 《新医学》 2009年第11期749-752,共4页 Journal of New Medicine
关键词 急性髓细胞白血病 复发性 联合化学治疗 靶向治疗 造血干细胞移植
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1周吉成,牛威林,卢玉英,赖永榕,杨日楷,程鹏.急性髓细胞白血病异常免疫表型的研究[J].新医学,1999,30(2):80-81. 被引量：1
  • 2VIRCHIS A, KOH M, RANKIN P, et aL Fludarabine, cytosine arabinoside, granulocyte,colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myel0dysplastic syndromes[J].Br J Haematol, 2004, 124 ( 1 ) : 26-32.
  • 3YAVUZ S, PAYDAS S, DISEL U, et al. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience [ J]. Am J Ther, 2006, 13 (5) : 389-393.
  • 4MONTILLO M, RICCI F, TEDESCHI A, et al. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia [ J ]. Leuk Res, 2009, 33 (8): 1072-1078.
  • 5HAROUSSEAU J L, LANCET J E, REIFFERS J, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia [ J ] . Blood, 2007, 109 (12) : 5151- 5156.
  • 6KARP J E, SMITH B D, GOJO I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myetogenous leukemia andpoorrisk features [ J ]. Clin Cancer Res, 2008, 14 ( 10 ) : 3077 -3082.
  • 7ISSA J P, GARCIA-MANERO G, GILES F J, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies [ J ]. Blood, 2004, 103 (5): 1635-1640.
  • 8LARSON R A, SIEVERS E L, STADTMAUER E A, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeioid leukemia in first recurrence[ J]. Cancer, 2005, 104 (7): 1442-1452.
  • 9TAKSIN A L, LEGRAND O, RAFFOUX E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study Of the alfa group[J]. Leukemia, 2007, 21 (1): 66-71.
  • 10CANDONI A, MARTINELLI G, TOFFOLETYI E, et al. Gemtuzumab-ozogamicin in combination with flu- darabine, cytarabine, idarubicin (FLAI-GO) as induc- tion therapy in CD33-positive AML patients younger than65 years[J]. Leuk Res, 2008, 32 (12) : 1800- 1808.

二级参考文献9

  • 1刘征辉,张学光,夏学鸣,郑列琳,陆廷伟,薛永权,阮长耿.免疫表型在急性髓细胞白血病中的预后价值[J].中华血液学杂志,1996,17(11):588-591. 被引量：22
  • 2麻柔,薛向军,公殿广,刘锋,杨经敏,马玲,杨留,王天恩,周霭祥.137例急性白血病免疫学表型分析[J].中华血液学杂志,1996,17(8):433-434. 被引量：19
  • 3陈珊珊，中国实验血液学杂志，1993年，1卷，1期，45页
  • 4中华血液学杂志，1986年，7卷，9期，565页
  • 5Au WY, Chan EC, Lie AK, et al. Poor engraftment after allogeneic bone marrow transplantation: role of chimerism analysis in treatment and outcome [J]. Ann Hematol, 2003,82(7):410-15.
  • 6Saarinen-Pihkala UM, Taskinen M, Vettenranta K, et al. Imminent allograft rejection prevented by donor lymphocyte transfusions: report of two pediatric cases [J].Bone Marrow Transplant, 2003,31(9):833-36.
  • 7Al Qurashi F, Ayas M, Al Sharif F, et al. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution[J]. Hematology, 2004, 9(2): 123-9.
  • 8Guardiola P, Kuentz M, Garban F, et al. Second early aUogeneie stem cell transplantation for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic amaemia[J]. Br J Haematol,2000, 111 (1):292-302.
  • 9丘镜滢,党辉,任汉云,王德炳,段爱君.自体血浆培养体系对改善白血病骨髓细胞染色体的研究[J].北京医科大学学报,1993,25(4):249-251. 被引量：46

共引文献10

同被引文献20

  • 1李一辉,王兴.白血病的治疗进展[J].华北煤炭医学院学报,2005,7(3):307-309. 被引量：1
  • 2任汉云,王茫桔.急性白血病的治疗进展[J].继续医学教育,2006,20(8):66-71. 被引量：2
  • 3Faded S, Gandhi V, Obrien s, et al. Result of a phase 1 - 2 study of clofarabine in combination with Ara. C in relapsed and refractory acute leukemia [ J ]. Blood, 105 (2) :940 - 947.
  • 4LARSON R A, SIEVERS E L ' STADTMAUER E A, et al. Final re- port of the eficacy and safety of gemtuzumab ozogamieln (Mylotarg)in patients with CD33 - positive acute myeloid leukemia in firs [ recur- renee [ J ]. Cancer,2005,104 (7) : 1442 - 1452.
  • 5Marcucci G, Moser B, BlumW ,'et al. A Phase Ⅲ randomized trial of intensive induction and consolidation chemotherapy oblimerson, a pro-apoptotic Bcl -2 antisense oligonueleotide in afttreated acute myeloid leukemia patients > 60 years old [J]. J ClinOncol, 2007,25 ( 18 Suppl ) :7012.
  • 6MARCUCCI G,BYRD J C ,DAI G,et al. Phase 1 and pharmacodyna- mic studies of G3139 ,a Bc1-2 antiscnse oligonucleotide,in combina- tion with chemotherapy in refractory or relapsed acute leukemia [ J]. Blood,2003,101 (2) :425 -432.
  • 7曹琦,韦国桢,郭红荣.三氧化二砷诱导恶性肿瘤细胞凋亡机制的研究进展[J].现代肿瘤医学,2007,15(5):731-734. 被引量：20
  • 8张亚停,综述,方建培,审校.难治及复发性急性髓细胞白血病的治疗进展[J].中国小儿血液与肿瘤杂志,2008,13(1):44-46. 被引量：3
  • 9李兆亮,滕清良.治疗其他疾病[J].山东医药,2009,49(11):109-110. 被引量：1
  • 10宋美艳,王意忠.急性髓细胞白血病的治疗进展[J].中国现代医药杂志,2009,11(4):125-127. 被引量：3

引证文献2

二级引证文献4

新医学
2009年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部